IPO

Me-too, In-Fashion Investing Fueling A Social Media Bubble

By John Steuart / May 24, 2012 / 2 Comments

I was struck recently by a piece in The Wall Street Journal by Pui-Wing Tam, The $1 Billion Club Gets Crowded, which highlights the amusing rate at which closely held, private US companies in the social media sector are garnering $1 billion-plus valuations. With 20 companies already fetching a 10-figure price tag— 15 of them since the beginning […]

Read More

IPOs look dicey, but private equity may pick up some of the slack

By Claremont Creek Alerts / September 15, 2011 / 0 Comments

September 15, 2011  source: Xconomy For a while, I was optimistic that 2011 would be a good year for venture capital-backed IPOs, and it wasn’t just wishful thinking. There were 72 VC-backed IPOs last year—six times as many as in 2009. The year ended with a bang and 2011 got off to a good start. […]

Read More

Molecular Diagnostics World Congress, Venture Capitalists’ Best Practices on Commercializing Innovation

By John Steuart / July 22, 2011 / 0 Comments

I will be moderating a panel, Venture Capitalists’ Best Practices on Commercializing Innovation at the Molecular Diagnostics World Congress on September 29, 2011 at the South San Francisco Conference Center. Here’s the panel topic summary, hope to see you there. Successful venture capital investing in molecular diagnostics requires proper commercialization of innovation. But how does this innovation get […]

Read More

What Does It Take to Swing the IPO Window Open for Biotechs? – Suggestions include selling at a discount at a time when there is a rising investor fan-base for social media.

By Claremont Creek Alerts / June 22, 2011 / 0 Comments

June 22, 2011  source: Genetic Engineering and Biotechnology News On June 10, a day after withdrawing an $86 million IPO filed in November 2010, Ambit Biosciences reported securing $30 million in Series D-2 equity financing. “The terms currently obtainable in the public marketplace are not sufficiently attractive to the registrant to warrant proceeding with the […]

Read More

Trends Bode Well For Clean Tech IPOs This Year

By Nat Goldhaber / April 25, 2011 / 2 Comments

March 2011  source: Financial Executives International (download a pdf reprint of the article) Over the years, venture capitalists have invested in clean technology and renewable energy with the expectation that returns will take a long time. The VCs were right. Development of technologies such as solar cell manufacturing, utility-scale renewable energy projects and genetically engineered […]

Read More

The Argument for the Secondary Market

By Randy Hawks / February 16, 2011 / 0 Comments

February 16, 2011  source: this guest blog post originally appeared on peHUB There has been a lot of buzz around highflying companies allowing sales of their stock on secondary trading platforms. There have always been opportunities for individual secondary sales in private companies but nothing to match the current level of action. Before, occasional private […]

Read More

Meet our team

Claremont Creek Ventures was founded in 2005 by Nat Goldhaber, John Steuart and Randy Hawks to pursue early stage investing in exceptional technology startups.

Nat_Boldhaber7718 -1200px

NAT GOLDHABER

Nat Goldhaber is a co-founder of Claremont Creek Ventures. 

TED DRISCOLL

Ted is an expert on digital health and diagnostics, from big data and health technology to genomics and personalized medicine.

Paul_Straub7765 -1200px

PAUL STRAUB

Paul is particularly focused on the potential of digital and business innovation to impact and advance broad-impact industries.

Brad_Webb8124 1200px crop

BRAD WEBB

Brad is focused on the role of genomics and biomarker data analytics in driving the next generation of diagnostics and drug development.

Randy_Hawks7690 -1200px

RANDY HAWKS

Randy Hawks is a co-founder of Claremont Creek Ventures.

Post Categories

Archives